GLAND
GLAND PHARMA LIMITED
Each stock's 10,000-path forecast, rendered as light.
GLAND PHARMA LIMITED (GLAND) Stock Analysis & Case Study
Is GLAND a good buy? The data-driven verdict.
GLAND PHARMA LIMITED (GLAND) trades at ₹2,601,on the numbers it tread carefully, a Downstox Snapshot Score of 33/100.
On the numbers, GLAND PHARMA LIMITED (GLAND) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 41.2× earnings, ROE of 10.7%, a 55% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
GLAND fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How GLAND ranks against the 2,373 companies in our screener
- GLAND's market cap of 42,908 Cr ranks in the 90th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- GLAND's book value of ₹629 ranks in the 93rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- GLAND's promoter holding of 51.8% ranks in the 35th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- GLAND's 3-year profit (PAT) growth of 8.0% ranks in the 40th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- GLAND's 3-year revenue growth of 21.0% ranks in the 75th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- GLAND's debt-to-equity ratio of 0.03x is lower than 90% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is GLAND overvalued? GLAND P/E vs peers
GLAND trades at 41.2× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
GLAND share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 5.6y of GLAND history (6%/yr drift, 31%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| GLAND 2027 | ₹1,831 | ₹2,717 | ₹4,032 | +4% |
| GLAND 2028 | ₹1,618 | ₹2,839 | ₹4,982 | +9% |
| GLAND 2029 | ₹1,485 | ₹2,966 | ₹5,926 | +14% |
| GLAND 2030 | ₹1,398 | ₹3,099 | ₹6,872 | +19% |
| GLAND 2031 | ₹1,340 | ₹3,238 | ₹7,827 | +24% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability GLAND goes up, or doubles?
The bull case for GLAND
- GLAND PHARMA LIMITED is part of the nifty100 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹5,926.
The bear case & risks
- GLAND's P/E of 41.2x is lower than 32% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- GLAND's return on equity of 10.7% ranks in the 53rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹1,485.
GLAND volatility & expected range, how bumpy is the ride?
Over the last 5.6 years GLAND compounded at 6%/year with annualized volatility of 31%. That volatility implies a 1-year 80% range of ₹1,831-₹4,032, the honest backbone behind any single price target.
GLAND price forecast, the full 60-month probability fan
GLAND price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds GLAND hits common targets within the simulated horizon?
Full multi-horizon detail on the GLAND price target & forecast page.
GLAND Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. GLAND scores 6/8, mixed financial health.
GLAND MTF margin & leverage across 11 brokers
Margin Trading Facility lets you buy GLAND with part of the capital. Lower margin % = higher leverage. Rates compared across 11 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 30.88% | 3.2× |
| Zerodha | 30.85% | 3.2× |
| Groww | 30.92% | 3.2× |
| DhanCHEAPEST | 30.85% | 3.2× |
| Kotak Neo | 30.86% | 3.2× |
| Paytm Money | 31.62% | 3.2× |
| Pocketful | 30.88% | 3.2× |
| Fyers | 31.25% | 3.2× |
| Anand Rathi | 30.85% | 3.2× |
| Bajaj Broking | 32.00% | 3.1× |
| Share India | 30.92% | 3.2× |
Compare every broker on the GLAND MTF page.
About GLAND PHARMA LIMITED: sector, index & market-cap context
GLAND PHARMA LIMITED (GLAND) is a mid-cap NSE-listed company, and a constituent of the Nifty 500 index, with a market capitalisation of ₹42,908 Cr. See more stocks on our screener.
How the GLAND Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of GLAND PHARMA LIMITED's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
GLAND analysis, FAQs
Is GLAND PHARMA LIMITED (GLAND) a good buy?
On the numbers, GLAND PHARMA LIMITED (GLAND) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 41.2× earnings, ROE of 10.7%, a 55% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is GLAND overvalued or undervalued?
GLAND trades at 41.2× earnings, expensive versus the ~22× long-run Nifty average.
What is the GLAND share price target for 2031?
GLAND's probability-weighted 2031 median target is ₹3,238, with an 80% range of ₹1,340-₹7,827 (10,000-path Monte-Carlo).
What is the probability GLAND doubles in 5 years?
The modelled probability of GLAND reaching ₹5,202 (2×) within 5 years is 25%.
What is the bull case for GLAND?
GLAND PHARMA LIMITED is part of the nifty100 universe with live, tracked fundamentals on Downstox.
What are the risks in GLAND?
GLAND's P/E of 41.2x is lower than 32% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. GLAND's return on equity of 10.7% ranks in the 53rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.